The BEYONDD Pilot Study: A Decentralized Community-Engaged Research Framework for Multimodal Characterization of Neurodegenerative Risk in a Multi-Ethnic, Midlife Cohort with Subjective Cognitive or Behavioral Complaints
Rivera Mindt, M.; Savin, M. J.; Guzman, V.; Arentoft, A.; Barragan, E.; Cubbellotti, S.; Heuer, H.; Kubo Germano, K.; Rosen, H.; Jun Cho, S.; Higuera, M.; Sotelo, M.; Ramirez, C.; Culhane, J.; Margolis, A.; Slaughter, A.; Calcetas, A.; Talavera, S.; Vincaludo, K.; DiBenedetto, J.; Ayo, O.; Cham, H.; Rabinovici, G. D.; Boxer, A. L.; Byrd, D. A.
Show abstract
Introduction: Alzheimers disease and related dementias (AD/ADRD) pathology begin decades before diagnosis, yet scalable risk detection infrastructures for midlife adults remain limited. The Biomarker Evaluation of Young Onset Dementia from Diverse Populations (BEYONDD; R56AG075744) pilot study was designed to address this gap through a decentralized, community-engaged research (CER) model for neurodegenerative risk detection in midlife adults with subjective cognitive or behavioral complaints (sCBC). Methods: This cross-sectional pilot assessed the feasibility of CER-based digital recruitment and participant completion of remotely-acquired screening, cognitive, clinical, and phlebotomy assessments with support of Community Research Navigators (CRNs). Feasibility was evaluated using digital recruitment metrics, yield, retention, and geographic reach. Results: Our approach generated 1.8+ million advertisement impressions,161,100 clicks, and 4,089 web-registrants. 2,117 individuals completed the online screener, exceeding the prespecified screening goal by 141%. We enrolled a multi-ethnic, midlife cohort of 579 participants (Mage=51.6[6.5]; 75% female; 44% Latinx, 31% non-Latinx Black-American, and 26% all other race/ethnicities), exceeding the enrollment goal by 290%, and 476 participants completed the remote protocol (82% retention). Participants were recruited from 49 U.S. states, Puerto Rico, Australia, and Canada. CRN engagement was concentrated during study stage transitions. Discussion: BEYONDDs decentralized, CER-based screening infrastructure demonstrated wide geographic reach, strong early-stage engagement, and efficient recruitment among diverse midlife adults. These findings support the feasibility of scalable CER-based digital recruitment for decentralized early detection initiatives and AD/ADRD trials.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Persistence of Neuropsychiatric Symptoms and Dementia Prognostication: A Comparison of Three Operational Definitions of Mild Behavioral Impairment 93%
- Clinical Validation and Machine Learning Optimization of MyCog: A Self-Administered Cognitive Screener for Primary Care Settings 93%
- Evaluation of a speech-based AI system for early detection of Alzheimer’s disease remotely via smartphones 93%
Similar papers in this journal
- Continuous Associations Between Remote Self-Administered Cognitive Measures and Imaging Biomarkers of Alzheimer’s Disease 94%
- Use of Lecanemab and Donanemab in the Canadian Healthcare System: Evidence, Challenges, and Areas for Future Research 92%
- Using Machine Learning and Electronic Health Record (EHR) Data for the Early Prediction of Alzheimer’s Disease and Related Dementias 92%
Similar papers in this journal
- A scoping review of remote and unsupervised digital cognitive assessments in preclinical Alzheimer’s disease 94%
- A Remote Digital Memory Composite to Detect Cognitive Impairment in Memory Clinic Samples in Unsupervised Settings using Mobile Devices 93%
- Interpretable deep learning approach for extracting cognitive features from hand-drawn images of intersecting pentagons in older adults 92%
Similar papers in this journal
- Race/Ethnic Disparities in Mild Cognitive Impairment and Dementia: The Northern Manhattan Study 92%
- A Multimodal Evaluation of Transcranial Photobiomodulation in Mild Cognitive Impairment: Cognitive, Metabolic, and Neuroimaging Outcomes of a Pilot Randomized Control Trial 92%
- A Qualitative Study of People with Alzheimer’s Disease in a Memory Clinic Considering Lecanemab Treatment 92%